Cefodizime sodium is a third generation cephalosporinantibioticwith a broad spectrum of antibacterial activity. Cefodizime sodium has no renal toxic effect, good tolerance and immune regulation activity, and can be used for the research of severe infections of the respiratory and urinary tracts^[1][2].

Enterobacteriaceae includingEscherichia coli,Klebsiella pneumoniae,Morganella morgan ii,Proteus mirabilis,Proteus vulgaris,Shigella sonnei,Yersinia enterocoliticaandSalmonellaspecies are all consistently sensitive to Cefodizime in vitro. Cefodizime has marginal but variable inhibitory activity againstCitrobacterspecies includingCitrobacter freundii, andSerratia marcescens. Cefodizime inhibits other Gram-negative bacteria includingHaemophilus irifluenzae,Moraxella catarrhalis,Neisseria gonorrhoeaeandNeisseria meningitidis^[1].
Cefodizime is a bactericidal antibiotic having high affinity for penicillin-binding proteins lA/B, 2 and 3 ofE. coli. The in vitro concentrations of Cefodizime resulting in bactericidal activity against susceptible strains of Gram-positive and Gram-negative bacteria are generally similar to the minimum inhibitory concentrations^[1].

In experimentally-inducedK. pneumoniaerespiratory tract infections in mice, Cefodizime has activity comparable to Cefotaxime and Ceftazidime, and greater than that of Cefoperazone, Latamoxef, Cefuroxime or cefazolin for 8 hours after a single subcutaneous dose of 50 mg/kg. However, unlike these cephalosporins, Cefodizime continues to demonstrate pronounced bactericidal activity for at least 48 hours after a single injection. Complete bacterial clearance from the lung is achieved within 48 hours in 50% of the mice although Cefodizime is no longer detectable in the serum^[1].

628.63

Solid

C₂₀H₁₈N₆Na₂O₇S₄

86329-79-5

头孢地嗪钠

Room temperature in continental US; may vary elsewhere.

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

H₂O : 100 mg/mL(159.08 mM;Need ultrasonic)

DMSO : 62.5 mg/mL(99.42 mM;Need ultrasonic)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： PBS

  Solubility: 100 mg/mL (159.08 mM); Clear solution; Need ultrasonic
• 2.

  请依序添加每种溶剂： 10% DMSO    40%PEG300   5%Tween-80   45% saline

  Solubility: ≥ 2.08 mg/mL (3.31 mM); Clear solution

  此方案可获得 ≥ 2.08 mg/mL (3.31 mM，饱和度未知) 的澄清溶液。

  以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

  将 0.9 g 氯化钠，完全溶解于 100 mL ddH2O 中，得到澄清透明的生理盐水溶液
• 3.

  请依序添加每种溶剂： 10% DMSO    90% (20%SBE-β-CDin saline)

  Solubility: ≥ 2.08 mg/mL (3.31 mM); Clear solution

  此方案可获得 ≥ 2.08 mg/mL (3.31 mM，饱和度未知) 的澄清溶液。

  以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

  将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明